Six Molecular Diagnostic Companies To Watch- CIRCULOGENE featured on Labiotech.eu
Labiotech.eu was founded in 2014 by two biotech engineers in response to the lack of digital media covering the European biotechnology industry. Their mission is to provide the biotech community with current and relevant information about the life sciences industry. https://www.labiotech.eu/best-biotech/molecular-diagnostics-companies/?trk=feed-detail_main-feed-card_feed-article-content#circulogene
Editorial by Dr. Paul Walker: Induction treatment in operable non-small cell lung cancer: the immune oncology era unfold
Induction treatment in operable non-small cell lung cancer: the immune oncology era unfolds Paul R. Walker^ Division of Hematology/Oncology, Department of Medicine, Brody School of Medicine at East Carolina University, Greenville, NC, USA Correspondence to: Paul R. Walker, MD, FACP. Division of Hematology/Oncology, Department of Medicine, Brody School of Medicine…
Research indicates that positive PD-L1 detected by CIRCULOGENE liquid biopsy can have favorable outcomes for cancer patients
Research indicates that positive PD-L1 detected by CIRCULOGENE liquid biopsy can have favorable outcomes for cancer patients Based on a 3-year, real-world study of patients with metastatic NSCLC, plasma cfRNA PD-L1 expression was as effective as tissue PD-L1 expression for informing ICI treatment benefit, and could identify additional patients who…
CIRCULOGENE’s liquid biopsy for PD-L1 status features in research presented at the recent AACR annual meeting
CIRCULOGENE’s liquid biopsy for PD-L1 status features in research presented at the recent AACR annual meeting Testing cancer patients for PD-L1 mRNA levels using CIRCULOGENE technology can improve patient selection for tailored therapies and avoid unnecessary treatment-related toxicity. BIRMINGHAM, Ala. and Pensacola, Fla. (May 12, 2023) – CIRCULOGENE is an…
CIRCULOGENE’s blood-based, gene panel is central to research presented at last weekend’s Digestive Disease Week 2023
CIRCULOGENE’s blood-based, gene panel is central to research presented at last weekend’s Digestive Disease Week 2023 Speed of delivery resulting from liquid biopsy techniques was a key factor in the ability of circulating tumor DNA reports to inform decision making for first-line cancer therapy. BIRMINGHAM, Ala. and Pensacola, Fla. (May…
CIRCULOGENE Announces Appointment of Bob Gasparini to Board of Directors
BIRMINGHAM, Ala. and Pensacola, Fla. (December 8, 2022) – CIRCULOGENE is an innovative liquid biopsy company transforming precision medicine through the rapid and cost-effective delivery of actionable results and the only laboratory in the world that reports levels of the immunotherapy biomarker PD-L1 with a simple blood test. CIRCULOGENE is proud to announce…
CIRCULOGENE shares results of remarkable rectal cancer study
FOR IMMEDIATE RELEASE CIRCULOGENE shares results of remarkable rectal cancer study Identifying mismatch repair-deficient (MMRd) or microsatellite instability (MSI) BIRMINGHAM, Ala. and Pensacola, Fla. (June 27, 2022) – CIRCULOGENE, an innovative medical technology company transforming precision medicine through the rapid delivery of actionable biomarkers, shares remarkable results from a revolutionary immunotherapy…
CIRCULOGENE presented plasma PD-L1 data at the American Society for Radiation Oncology (ASTRO) / American Society of Clinical Oncology (ASCO) Multidisciplinary Thoracic Cancers Symposium
FOR IMMEDIATE RELEASE CIRCULOGENE presented plasma PD-L1 data at the American Society for Radiation Oncology (ASTRO) / American Society of Clinical Oncology (ASCO) Multidisciplinary Thoracic Cancers Symposium Liquid PD-L1 data demonstrates clinical utility in lung cancer patients BIRMINGHAM, Ala. and Pensacola, Fla. (December 2, 2021) – CIRCULOGENE, an innovative medical technology company transforming…
CIRCULOGENE Announces Lab Expansion in Florida
FOR IMMEDIATE RELEASE CIRCULOGENE Announces Lab Expansion in Florida Liquid Biopsy Company Laboratory Operations Are Growing in Pensacola BIRMINGHAM, Ala. and Pensacola, Fla. (October 14, 2021) – CIRCULOGENE, an innovative medical technology company transforming precision medicine through the rapid delivery of actionable results, and the only company in the world with a liquid…
CIRCULOGENE Announces Issuance of U.S. Patent for Method of Preparing Cell-Free Nucleic Acid Molecules by In Situ Amplification
Issued patent recognizes CIRCULOGENE’s novel method of enriching cfDNA without DNA isolation, extraction or purification, enabling “in situ” genetic manipulation of biofluid samples. BIRMINGHAM, Ala. – CIRCULOGENE, an innovative molecular diagnostics company transforming precision medicine through the rapid delivery of actionable results, announced today that the United States Patent and…